Streetbeat News

Analyst Ratings

ZM

Wedbush analyst Taz Koujalgi has maintained a Neutral rating on Zoom Video Communications (ZM) and kept the price target at $80.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 2:01 pm

PLYA

Truist Securities analyst Patrick Scholes has maintained a Buy rating on Playa Hotels & Resorts (NASDAQ:PLYA) and increased the price target from $13 to $14.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 2:00 pm

IQV

Truist Securities analyst Jailendra Singh has maintained a Buy rating on IQVIA Holdings (IQV) and increased the price target from $286 to $297.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:59 pm

CELH

Wedbush analyst Gerald Pascarelli maintains an Outperform rating on Celsius Holdings (CELH) with a $75 price target.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:58 pm

JPM

QCOM

STLD

URNM

On CNBC's 'Halftime Report Final Trades,' analysts recommended North Shore Global Uranium Mining ETF (URNM), JPMorgan Chase & Co. (JPM), Steel Dynamics, Inc. (STLD), and Qualcomm Inc. (QCOM) based on various factors including market trends, company performance, and economic forecasts. JPMorgan's CEO Jamie Dimon expressed concerns about a potential U.S. economic recession, while Steel Dynamics announced a dividend increase, and Qualcomm reported a revenue beat.

Portfolio Pulse from Avi Kapoor

February 27, 2024 | 1:58 pm

HIMS

Truist Securities analyst Jailendra Singh has maintained a Hold rating on Hims & Hers Health (NYSE:HIMS) and increased the price target from $10 to $13.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:57 pm

JANX

Wedbush analyst David Driscoll maintains an Outperform rating on Janux Therapeutics (NASDAQ:JANX) and raises the price target from $24 to $53.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:56 pm

HSII

Truist Securities analyst Tobey Sommer has maintained a Hold rating on Heidrick & Struggles Intl (NASDAQ:HSII) and increased the price target from $27 to $30.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:55 pm

FRPT

Truist Securities analyst Bill Chappell has maintained a Hold rating on Freshpet (NASDAQ:FRPT) and increased the price target from $70 to $120.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:54 pm

RVMD

Wedbush analyst David Driscoll has maintained an Outperform rating on Revolution Medicines (NASDAQ:RVMD) and increased the price target from $41 to $42.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:53 pm